Form 8-K

8-K — Immunome Inc.

Accession: 0001193125-26-413217

Filed: 2026-10-05

Period: 2026-10-02

CIK: 0001472012

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Entry into a Material Definitive Agreement

Item: Unregistered Sales of Equity Securities

Item: Financial Statements and Exhibits

Documents

8-K — d114908d8k.htm (Primary)

EX-4.1 (d114908dex41.htm)

EX-10.1 (d114908dex101.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: d114908d8k.htm · Sequence: 1

8-K

Immunome Inc. NASDAQ false 0001472012 0001472012 2026-10-02 2026-10-02

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 2, 2026

Immunome, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-39580

77-0694340

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

18702 N. Creek Parkway, Suite 100

Bothell, Washington

98011

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (425) 939-7410

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, $0.0001 par value per share

IMNM

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01

Entry into a Material Definitive Agreement.

Amendment to License Agreement

On October 2, 2026, Immunome, Inc. (the “Company”) entered into Amendment No. 4 to License Agreement (the “Amendment”) with Bristol-Myers Squibb Company (“BMS”) to further amend the License Agreement, by and between BMS and the Company (as assignee of Ayala Pharmaceuticals, Inc.), dated as of November 29, 2017 (as amended, the “License Agreement”). The Amendment removes the Company’s obligation to make any milestone and royalty payments under the License Agreement and assigns to the Company patent rights related to varegacestat (formerly AL102) and AL101 that were previously licensed to the Company under the License Agreement.

As consideration for the Amendment, the Company paid BMS $20.0 million in cash and issued 4,425,487 shares of the Company’s common stock (collectively, the “Amendment Consideration”). Following payment of the Amendment Consideration, the Company has no milestone, royalty or other payment obligations to BMS under the License Agreement or the Amendment.

Stock Issuance Agreement

Concurrently with the execution of the Amendment, the Company entered into a stock issuance agreement (the “Stock Issuance Agreement”) with BMS, pursuant to which the Company issued 4,425,487 shares of the Company’s common stock (the “Shares”), as partial consideration for entering into the Amendment.

The Company has agreed to use its commercially reasonable efforts to (x) file a resale registration statement with the Securities and Exchange Commission (the “SEC”) registering the Shares for resale by November 16, 2026 and (y) cause such resale registration statement to be declared effective as soon as practicable after the filing thereof but no later than 60 calendar days after the filing thereof or by 5 business days from when the Company is notified that the SEC will not review the resale registration statement or that it will not be subject to further review.

The Company has also agreed to, among other things, indemnify BMS, its affiliates, partners, members, officers, directors, agents and representatives from certain liabilities and pay all fees and expenses (excluding any legal fees of BMS, and any underwriting discounts and selling commissions) incident to the Company’s obligations under the Stock Issuance Agreement.

The foregoing summary of the Amendment is not complete and is qualified in its entirety by reference to the Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K, the License Agreement, a copy of which was filed as Exhibit 10.1 to our Current Report on Form 8-K filed on March 26, 2024, the Amendment No. 2 to License Agreement, dated August 7, 2024, a copy of which was filed as Exhibit 10.2 to our Quarterly Report on Form 10-Q filed on November 13, 2024, and Amendment No. 3 to License Agreement, dated March 27, 2026, a copy of which was filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q filed on May 12, 2026. Additionally, the foregoing summary of the Stock Issuance Agreement is not complete and is qualified in its entirety by reference to the Stock Issuance Agreement, a copy of which is filed as Exhibit 4.1 to this Current Report on Form 8-K.

Item 3.02

Unregistered Sales of Equity Securities

See the description set forth under Item 1.01 above with respect to the Stock Issuance Agreement, which is incorporated into this Item 3.02 by reference. The Shares are being issued to BMS pursuant to the exemption from the registration requirements provided in Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), for transactions by an issuer not involving any public offering. Accordingly, the Shares have not been registered under the Securities Act and may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act.

Item 9.01

Financial Statements and Exhibits

(d)

Exhibit

Number

Description

4.1

Stock Issuance Agreement dated October 2, 2026, by and between the Company and Bristol-Myers Squibb Company

10.1*+

Amendment No. 4 to License Agreement dated October 2, 2026, by and between the Company and Bristol-Myers Squibb Company

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

Certain information in this exhibit is omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K because it is both not material and is the type that the registrant treats as private or confidential.

Schedules and exhibits to the agreement have been omitted pursuant to Item 601(a)(5) of Regulation S-K.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

IMMUNOME, INC.

Date: October 5, 2026

By:

/s/ Clay Siegall

Clay Siegall, Ph.D.

President and Chief Executive Officer

EX-4.1

Filename: d114908dex41.htm · Sequence: 2

EX-4.1

Exhibit 4.1

STOCK ISSUANCE AGREEMENT

THIS STOCK ISSUANCE AGREEMENT

(“Agreement”) is entered into as of October 2, 2026, by and between Bristol-Myers Squibb Company, a Delaware corporation having offices at Route 206 and Province Line Road, Princeton, New Jersey 08543

(“BMS”), and Immunome, Inc., a Delaware corporation having an office at 18702 N. Creek Parkway, Suite 100, Bothell, Washington 98011 (“Immunome”). Immunome and BMS are together

referred to in this Agreement as the “Parties” and individually as a “Party.”

RECITALS

Subject to and in accordance with the terms and provisions of this Agreement, Immunome has agreed to issue, and BMS has agreed to acquire,

4,425,487 shares (the “Shares”) of Immunome’s common stock, par value $0.0001 per share (the “Common Stock”), as partial consideration for entering into that certain Amendment No. 4 to

License Agreement (the “Amendment”) as of even date herewith, by and between Immunome and BMS, which amends that certain License Agreement, dated as of November 29, 2017 by and between Immunome and BMS (as amended, the

“License Agreement”), the value of which Immunome has determined as of the date hereof exceeds the par value of the Shares to be issued hereunder.

AGREEMENT

For good and valuable consideration, the Parties agree as follows:

Section 1. STOCK ISSUANCE

1.1 Issuance and Acquisition of Stock. Subject to the terms and conditions of this Agreement, Immunome will issue to BMS, and BMS

will acquire from Immunome, the Shares as partial consideration for entering into the Amendment.

1.2 Closing. The closing

hereunder (the “Closing”) shall occur remotely via the exchange of signatures on the date of this Agreement at such time as mutually agreed upon, orally or in writing, by Immunome and BMS. At the Closing, Immunome shall

instruct its transfer agent to register the Shares in book entry form in BMS’s name on Immunome’s share register and shall cause its transfer agent to prepare and deliver to BMS an account statement reflecting the issuance as promptly as

possible following the Closing.

Section 2. REPRESENTATIONS AND WARRANTIES OF

IMMUNOME

Except as otherwise specifically contemplated by this Agreement, Immunome hereby represents and warrants as of

the date hereof to BMS that:

2.1 Private Placement. Neither Immunome nor any person acting on its behalf, has, directly or

indirectly, made any offers or sales of any security or solicited any offers to buy any security, under any circumstances that would require registration of the Shares under the Securities Act of 1933, as amended (the “Securities

Act”). Subject to the accuracy of the representations and warranties made by BMS in Section 3, the Shares will be issued and sold to BMS in compliance with applicable exemptions from the registration and

prospectus delivery requirements of the Securities Act and the registration and qualification requirements of all applicable securities laws of the states of the United States. Immunome has not engaged any brokers, finders or agents, or incurred, or

will incur, directly or indirectly, any liability for brokerage or finder’s fees or agents’ commissions or any similar charges in connection with this Agreement and the transactions contemplated hereby.

2.2 Organization and Qualification. Immunome is duly incorporated, validly

existing and in good standing under the laws of the State of Delaware, with full corporate power and authority to conduct its business as currently conducted. Immunome is duly qualified to do business and is in good standing in every jurisdiction in

which the nature of the business conducted by it or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, would not reasonably be expected to (i) have a

material adverse effect on the business, assets, liabilities, financial condition, results of operations, or stockholders’ equity of Immunome and its subsidiaries, taken as a whole, or (ii) materially adversely affect the validity of the

Shares or the legal authority of Immunome to comply in all material respects with this Agreement (clauses (i) and (ii), a “Material Adverse Effect”).

2.3 Subsidiaries. Each direct or indirect subsidiary of Immunome that owns any assets material to Immunome has been duly

incorporated or organized, as the case may be, and is validly existing as a corporation, partnership or limited liability company, as applicable, in good standing under the laws of the jurisdiction of its incorporation or organization and has the

power and authority (corporate or other) to own, lease and operate its properties and to conduct its business as presently conducted. Each subsidiary is duly qualified as a foreign corporation, partnership or limited liability company, as

applicable, to do business and is in good standing in each jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure to so qualify or be in

good standing would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect on Immunome. All of the issued and outstanding capital stock or other equity or ownership interests of each subsidiary have been duly

authorized and validly issued, are fully paid and nonassessable and are owned by Immunome, directly or through subsidiaries, free and clear of any encumbrances or preemptive and similar rights to subscribe for or purchase securities.

2.4 Authorization; Enforcement. Immunome has all requisite corporate power and authority to enter into and to perform its

obligations under this Agreement, to consummate the transactions contemplated hereby and to issue the Shares in accordance with the terms hereof. The execution, delivery and performance of this Agreement by Immunome and the consummation by it of the

transactions contemplated hereby (including the issuance of the Shares in accordance with the terms hereof) have been duly authorized by Immunome’s board of directors and no further consent or authorization of Immunome, its board of directors,

or its stockholders is required. This Agreement has been duly executed by Immunome and constitutes a legal, valid and binding obligation of Immunome enforceable against Immunome in accordance with its terms, except as enforceability may be limited

by applicable bankruptcy, insolvency, reorganization, or moratorium or similar laws affecting creditors’ and contracting parties’ rights generally and except as enforceability may be subject to general principles of equity and except as

rights to indemnity and contribution may be limited by state or federal securities laws or public policy underlying such laws.

2.5

Issuance of Shares. The Shares are duly authorized and, upon issuance in accordance with the terms of this Agreement, will be validly issued, fully paid and non-assessable and free and clear of any

liens, encumbrances or other restrictions (other than those imposed by securities laws generally or this Agreement) and will not be subject to preemptive rights or other similar rights of stockholders of Immunome.

2.6 SEC Documents, Financial Statements.

(a) All material statements, reports, schedules, forms and other documents required to have been filed by Immunome or its officers with

the SEC have been so filed on a timely basis. As of the time it was filed with the United States Securities and Exchange Commission (“SEC”) (or, if amended or superseded by a filing prior to the date of this Agreement, then

on the date of such filing), each of the statements, reports, schedules, forms and other documents filed by Immunome with the SEC since January 1, 2024 (the “SEC Documents”) complied in all material respects with the

applicable requirements of the

Securities Act or the Exchange Act of 1934, as amended (the “Exchange Act”) (as the case may be) and, as of the time they were filed, none of the SEC Documents contained

any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. The

certifications and statements required by (i) Rule 13a-14 under the Exchange Act and (ii) 18 U.S.C. §1350 (Section 906 of the Sarbanes-Oxley Act) relating to the SEC Documents are accurate and

complete and comply as to form and content with all applicable Laws. As used in this Section 2.6, the term “file” and variations thereof shall be broadly construed to include any manner in which a

document or information is furnished, supplied or otherwise made available to the SEC.

(b) The financial statements (including any

related notes) contained or incorporated by reference in the SEC Documents: (i) complied as to form in all material respects with the published rules and regulations of the SEC applicable thereto; (ii) were prepared in accordance with GAAP

(except as may be indicated in the notes to such financial statements or, in the case of unaudited financial statements, except as permitted by the SEC on Form 10-Q under the Exchange Act, and except that the

unaudited financial statements may not contain footnotes and are subject to normal and recurring year-end adjustments that are not reasonably expected to be material in amount) applied on a consistent basis

unless otherwise noted therein throughout the periods indicated; and (iii) fairly present, in all material respects, the financial position of Immunome and its consolidated subsidiaries as of the respective dates thereof and the results of

operations and cash flows of Immunome and its consolidated subsidiaries for the periods covered thereby. Other than as expressly disclosed in the SEC Documents filed prior to the date of this Agreement, there has been no material change in

Immunome’s accounting methods or principles that would be required to be disclosed in Immunome’s financial statements in accordance with GAAP. The books of account and other financial records of Immunome and each of its subsidiaries are

true and complete in all material respects.

respects with the applicable provisions of the Sarbanes-Oxley Act and the applicable current listing and governance rules and regulations of Nasdaq.

2.7 Internal Control; Disclosure Controls and Procedures.

(a) Immunome maintains a system of internal control over financial reporting (as defined in Rules

13a-15(f) and 15d-15(f) of the Exchange Act) that is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of

financial statements for external purposes in accordance with GAAP, including policies and procedures that (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect Immunome’s transactions and

dispositions of assets, (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, (iii) that receipts and expenditures are made only in accordance

with authorizations of management and Immunome’s board of directors, and (iv) provide reasonable assurance regarding prevention or timely detection of the unauthorized acquisition, use or disposition of Immunome’s assets that could

have a material effect on Immunome’s financial statements. Immunome has evaluated the effectiveness of its internal control over financial reporting as of December 31, 2025, and, to the extent required by applicable Law, presented in any

applicable SEC Document that is a report on Form 10-K or Form 10-Q (or any amendment thereto) its conclusions about the effectiveness of the internal control over

financial reporting as of the end of the period covered by such report or amendment based on such evaluation. Immunome has disclosed, based on its most recent evaluation of internal control over financial reporting, to Immunome’s auditors and

the audit committee of its board of directors: (A) all significant deficiencies and material weaknesses, if any, in the design or operation of internal control over financial reporting that are reasonably likely to adversely affect

Immunome’s ability to record, process, summarize and report financial information and (B) any known fraud, whether or not material, that involves management or other employees who have a significant role in Immunome’s or its

subsidiaries’ internal control over financial reporting. Immunome has not identified, based on its most recent evaluation of internal control over financial reporting, any material weaknesses in the design or operation of Immunome’s

internal control over financial reporting.

(b) Immunome maintains “disclosure controls and procedures” (as defined

in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) that are reasonably designed to ensure that information required to be disclosed by Immunome in the periodic

reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the required time periods, and that all such information is accumulated and communicated to Immunome’s management as appropriate to

allow timely decisions regarding required disclosure.

2.8 Capitalization and Voting Rights.

(a) The authorized capital of Immunome as of the date hereof consists of: (i) 300,000,000 shares of Common Stock of which, as of

June 30, 2026, (w) 113,399,202 shares were issued and outstanding, (x) 9,695,163 shares were reserved for issuance pursuant to Immunome’s equity incentive plans (including its stock purchase plan), (y) 16,926,110 shares were issuable upon

the exercise of stock options outstanding, and (z) no shares were issuable upon exercise of outstanding warrants, and (ii) 10,000,000 shares of Preferred Stock, of which no shares are issued and outstanding as of the date of this

Agreement. All of the issued and outstanding shares of Common Stock (A) have been duly authorized and validly issued, (B) are fully paid and non-assessable and (C) were issued in material

compliance with all applicable federal and state securities laws and not in violation of any preemptive rights.

(b) All of the

authorized shares of Common Stock are entitled to one (1) vote per share.

agreement or understanding relating to the voting of shares of capital stock of Immunome or the giving of written consents by a stockholder or director of Immunome.

2.9 No Conflicts; Government Consents and Permits.

(a) The execution, delivery and performance of this Agreement by Immunome and the consummation by Immunome of the transactions

contemplated hereby (including the issuance of the Shares) will not (i) conflict with or result in a violation of any provision of Immunome’s Amended and Restated Certificate of Incorporation, as amended, or Amended and Restated Bylaws,

(ii) violate or conflict with, or result in a breach of any provision of, or constitute a default under, any agreement, indenture, or instrument to which Immunome or any of its subsidiaries is a party, or (iii) result in a violation of any

law, rule, regulation, order, judgment or decree (including United States federal and state securities laws and regulations and regulations of any self-regulatory organizations) applicable to Immunome, except in the case of clauses (ii) and

(iii) only, for such conflicts, breaches, defaults, and violations as would not reasonably be expected to have a Material Adverse Effect on Immunome or result in a liability for BMS.

(b) Immunome is not required to obtain any consent, authorization or order of, or make any filing or registration with, any court or

governmental agency or any regulatory or self-regulatory agency in order for it to execute, deliver or perform any of its obligations under this Agreement in accordance with the terms hereof, or to issue and sell the Shares in accordance with the

terms hereof other than such as have been made or obtained, and except for (i) any post-closing filings required to be made under federal or state securities laws, and (ii) any required filings or notifications regarding the issuance or

listing of additional shares with Nasdaq.

2.10 Litigation. Except for such matters as have not had or would not

reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect, there is no (i) action, suit, claim or other proceeding, in each case by or before any governmental authority pending, or, to the knowledge of

Immunome, threatened against Immunome or any of its subsidiaries or (ii) judgment, decree, injunction, ruling or order of any governmental entity or arbitrator outstanding against Immunome or any of its subsidiaries. The aggregate of all

pending legal or governmental proceedings to which Immunome or any of its subsidiaries is a party to or of which any of their respective property or assets is the subject of that are not described in the SEC Documents, including ordinary routine

litigation incidental to the business, would not reasonably be expected to have a Material Adverse Effect.

2.11

Licenses/Compliance with Laws. Immunome possesses all licenses, certificates, permits and other authorizations issued by all applicable authorities necessary to conduct its business, and Immunome has not received any notice of proceedings

relating to the revocation or modification of any such certificate, authorization or permit which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would have a Material Adverse Effect.

2.12 Intellectual Property. Immunome owns or possesses or believes it can acquire on commercially reasonable terms sufficient

legal rights to all patents, patent applications, trademarks, trademark applications, service marks, service mark applications, tradenames, copyrights, trade secrets, domain names, mask works, information and proprietary rights and processes,

similar or other Intellectual Property Rights, subject matter of any of the foregoing, tangible embodiments of any of the foregoing, licenses in, to and under any of the foregoing, and any and all such cases as are necessary to Immunome in the

conduct of its business as now conducted and as presently proposed to be conducted (the “Immunome Intellectual Property”) without, to Immunome’s knowledge, any conflict with, or infringement of, the rights of others.

Except as described in the SEC Documents, (a) to Immunome’s knowledge, there are no rights of third parties to any Immunome Intellectual Property owned by Immunome; (b) to Immunome’s knowledge, there is no material infringement

by third parties of any Immunome Intellectual Property; (c) there is no pending, or to Immunome’s knowledge, threatened action, suit, proceeding or claim by others challenging Immunome’s rights in or to any such Immunome

Intellectual Property, and, to Immunome’s knowledge, Immunome is aware of no factual basis for any such claim; and (d) there is no pending or, to Immunome’s knowledge, threatened action, suit, proceeding or claim by others

challenging the validity or scope of any such Immunome Intellectual Property, including interferences, oppositions, inter partes reviews, reexaminations or government proceedings. To Immunome’s knowledge, no product or service marketed or sold

(or proposed to be marketed or sold) by Immunome violates any license or infringes any Intellectual Property Rights of any other party. Other than with respect to commercially available software products under standard

end-user object code license agreements or as described in the SEC Documents, there are no outstanding options, licenses, agreements, claims, encumbrances, security interests, liens or shared ownership

interests of any kind relating to any material Immunome Intellectual Property, nor is Immunome bound by or a party to any options, licenses or agreements of any kind with respect to the patents, trademarks, service marks, trade names, copyrights,

trade secrets, licenses, information, proprietary rights and processes of any other person. Immunome has not received any written communications alleging that Immunome has violated, or by conducting its business, would violate any of the patents,

trademarks, service marks, tradenames, or copyrights of any third party.

2.13 Taxes and Tax Returns. Immunome and each of

its subsidiaries have timely filed all income Tax Returns and other material Tax Returns that they were required to file under applicable Law. All such Tax Returns are correct and complete in all material respects and have been prepared in

compliance with all applicable Law. No written claim has ever been made by any Governmental Authority in any jurisdiction where Immunome or any of its subsidiaries does not file a particular Tax Return or pay a particular Tax that Immunome or such

subsidiary is subject to taxation by that jurisdiction.

2.14 Absence of Certain Changes. Between the date of the balance sheet of

Immunome set forth in its quarterly report on Form 10-Q for the quarter ended June 30, 2026 and the date hereof, except as disclosed in the SEC Documents, there has not been any Material Adverse Effect

with respect to Immunome.

2.15 Brokers or Finders Fees. No broker, finder, investment banker, or other person is entitled to

any brokerage, finder’s or other similar fee or commission from Immunome in connection with the transactions contemplated by this Agreement.

2.16 Not an Investment Company. Immunome is not an “investment company” within the meaning of the Investment Company

Act of 1940, as amended.

2.17 FCPA. None of Immunome, any of its subsidiaries, any director or officer of any of the

foregoing, or, to the knowledge of Immunome, any agent, employee or affiliate of any of the foregoing, is aware of or has knowingly taken or will take any action, directly or indirectly, that would result in a violation by such persons of the

Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (collectively, the “FCPA”), or any other applicable anti-corruption or anti-bribery laws, including, without limitation, making use

of the mails or any means or instrumentality of interstate commerce corruptly in furtherance of an offer, payment, promise to pay, or authorization or approval of the payment or giving of money, property, gifts or anything else of value, directly or

indirectly, to any “foreign official” (as such term is defined in the FCPA) or any foreign political party or official thereof or any candidate for foreign political office, in contravention of the FCPA or any other applicable

anti-corruption or anti-bribery laws.

2.18 Anti-Money Laundering. No action, suit or proceeding by or before any court or

governmental agency, authority or body or any arbitrator involving Immunome or any of its subsidiaries with respect to the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all applicable

jurisdictions, the rules and regulations thereunder or any related or similar rules, regulations or guidelines issued, administered or enforced by any governmental authority with jurisdiction over Immunome or its subsidiaries is pending or, to the

knowledge of Immunome, threatened.

2.19 OFAC. None of Immunome, any of its subsidiaries, any director or officer of any of

the foregoing, or, to the knowledge of Immunome, any employee, agent, controlled affiliate or representative of the foregoing, is a person that is, or is owned or controlled by a person that is currently subject to, any U.S. sanctions administered

by the Office of Foreign Assets Control of the U.S. Treasury Department (“OFAC”) or any other applicable sanction laws; and Immunome will not knowingly directly or indirectly use the proceeds from the License

Agreement, or knowingly lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person, to (i) fund or facilitate any activities or business of or with any person that, at

the time of such funding or facilitation, is subject to any U.S. sanctions administered by OFAC or any other applicable sanctions laws or (ii) in any other manner that will result in a violation of any U.S. sanctions

administered by OFAC or any other applicable sanctions laws by any person.

2.20 Regulatory Permits. Except as would not,

individually or in the aggregate, result in a Material Adverse Effect: (a) Immunome is and has been in compliance with statutes, laws, ordinances, rules and regulations applicable to it for the ownership, testing, development, manufacture,

packaging, processing, use, labeling, storage, or disposal of any product manufactured by or on behalf of Immunome or out-licensed by Immunome, including without limitation, the Federal Food, Drug, and

Cosmetic Act, 21 U.S.C. § 301, et seq., the Public Health Service Act, 42 U.S.C. § 262, similar laws of other Governmental Authorities and the regulations promulgated pursuant to such laws (collectively, “Applicable

Laws”); (b) Immunome possesses all licenses, certificates, approvals, authorizations, permits and supplements or

amendments thereto required by any such Applicable Laws and/or for the ownership of its properties or the conduct of its business as described in the SEC Documents (collectively,

“Authorizations”) and such Authorizations are valid and in full force and effect and Immunome is not in violation of any term of any such Authorizations; (c) Immunome has not received any written notice of adverse

finding, warning letter or other written correspondence or notice from the U.S. Food and Drug Administration (“FDA”) or any other Governmental Authority alleging or asserting noncompliance with any Applicable Laws or

Authorizations; (d) Immunome has not received notice of any ongoing claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any Governmental Authority or third party alleging that any product,

operation or activity is in violation of any Applicable Laws or Authorizations or has any knowledge that any such Governmental Authority or third party is considering any such claim, litigation, arbitration, action, suit, investigation or

proceeding, nor, to the best of Immunome’s knowledge, has there been any noncompliance with or violation of any Applicable Laws by Immunome that could reasonably be expected to require the issuance of any such written notice or result in an

investigation, corrective action, or enforcement action by FDA or similar Governmental Authority; (e) Immunome has not received notice that any Governmental Authority has taken, is taking or intends to take action to limit, suspend, modify or

revoke any Authorizations or has any knowledge that any such Governmental Authority has threatened or is considering such action; and (f) Immunome has filed, obtained, maintained or submitted all reports, documents, forms, notices,

applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or

amendments were complete, correct and not misleading on the date filed (or were corrected or supplemented by a subsequent submission). To Immunome’s knowledge, none of Immunome or any of its directors, officers, employees or agents, has made,

or caused the making of, any false statements on, or material omissions from, any other records or documentation prepared or maintained to comply with the requirements of the FDA or any other Governmental Authority.

2.21 Regulatory Compliance. The studies, tests and preclinical and clinical trials conducted by Immunome have been and, if still

pending, are being conducted in all material respects pursuant to all Applicable Laws and Authorizations. Immunome has not received any written notices or correspondence from any Governmental Authority requiring the termination or suspension of any

clinical studies conducted by or on behalf of, or sponsored by, Immunome or in which Immunome or its current products or product candidates have participated.

Section 3. REPRESENTATIONS AND WARRANTIES OF BMS

Except as otherwise specifically contemplated by this Agreement, BMS hereby represents and warrants as of the date hereof to Immunome that:

3.1 Authorization; Enforcement. BMS has the requisite corporate or other similar power and authority to enter into this

Agreement and to consummate the transactions contemplated hereby. BMS has taken all necessary corporate or other similar action to authorize the execution, delivery and performance of this Agreement. Upon the execution and delivery of this

Agreement, this Agreement will constitute a valid and binding obligation of BMS enforceable against BMS in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar

laws affecting creditors’ and contracting parties’ rights generally and except as enforceability may be subject to general principles of equity and except as rights to indemnity and contribution may be limited by state or federal

securities laws or public policy underlying such laws.

3.2 No Conflicts.

(a) The execution, delivery and performance of this Agreement by BMS and the consummation by BMS of the transactions contemplated hereby

(including the issuance of the Shares) will not (i) conflict with or result in a violation of any provision of BMS’s Certificate of Incorporation, as amended, or Bylaws, (ii) violate or conflict with, or result in a breach of any

provision of, or constitute a default under, any agreement, indenture, or instrument to which BMS is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including U.S. federal and state securities

laws and regulations and regulations of any self-regulatory organizations) applicable to BMS, except in the case of clauses (ii) and (iii) only, for such conflicts, breaches, defaults, and violations as would not reasonably be expected to have

a material adverse effect on the business, assets, liabilities, financial condition, results of operations, or stockholders’ equity of BMS and its subsidiaries, taken as a whole.

(b) BMS is not required to obtain any consent, authorization or order of, or make any filing or registration with, any court or

hereof other than such as have been made or obtained.

3.3 Investment Purpose. BMS is purchasing the Shares for its own

account and not with a present view toward the public distribution thereof and has no arrangement or understanding with any other persons regarding the distribution of such Shares except as would not result in a violation of the Securities Act. BMS

will not, directly or indirectly, offer, sell, pledge, transfer or otherwise dispose of (or solicit any offers to buy, purchase or otherwise acquire or take a pledge of) any of the Shares except in accordance with the Securities Act and to the

extent permitted by Section 4.1.

3.4 Reliance on Exemptions. BMS understands that Immunome intends

for the Shares to be offered and sold to it in reliance upon specific exemptions from the registration requirements of United States federal and state securities laws and that Immunome is relying upon the truth and accuracy of, and BMS’s

compliance with, the representations, warranties, agreements, acknowledgments and understandings of BMS set forth herein in order to determine the availability of such exemptions and the eligibility of BMS to acquire the Shares.

3.5 Accredited Investor; Access to Information. BMS is an “accredited investor” as defined in Regulation D under the

Securities Act and is knowledgeable, sophisticated and experienced in making, and is qualified to make decisions with respect to investments in shares presenting an investment decision like that involved in the acquisition of the Shares. BMS has

been furnished with, or otherwise had access to, materials relating to the offer and sale of the Shares, that have been requested by BMS, including, without limitation, Immunome’s public filings made available on the SEC’s electronic

data gathering and retrieval system (EDGAR) as of the date hereof (the “SEC Filings”), and BMS has had the opportunity to review such materials. BMS has been afforded the opportunity to ask questions of Immunome. Neither

such inquiries nor any other investigation conducted by or on behalf of BMS or its representatives or counsel will modify, amend or affect BMS’s right to rely on the truth, accuracy and completeness of the SEC Filings and Immunome’s

representations and warranties contained in this Agreement.

3.6 Restricted Securities. BMS understands that the Shares will

be characterized as “restricted securities” under the U.S. federal securities laws inasmuch as they are being acquired from Immunome in a private placement under Section 4(a)(2) of the Securities Act and that under such laws and

applicable regulations such Shares may be resold without registration under the Securities Act only in certain limited circumstances.

3.7 Ownership of Immunome Common Stock. As of the date hereof and as of

immediately prior to the Closing, BMS does not, directly or indirectly, own or have voting control over any shares of Immunome’s Common Stock.

Section 4. TRANSFER, RESALE, LEGENDS.

4.1 Transfer or Resale. BMS understands that:

(a) other than as provided by Section 5, the Shares have not been and are not being registered under the

Securities Act or any applicable state securities laws and, consequently, BMS may have to bear the risk of owning the Shares for an indefinite period of time because the Shares may not be transferred unless (i) the resale of the Shares is

registered pursuant to an effective registration statement under the Securities Act; (ii) BMS has delivered to Immunome an opinion of counsel (in form, substance and scope customary for opinions of counsel in comparable transactions) to the

effect that the Shares to be sold or transferred may be sold or transferred pursuant to an exemption from such registration; or (iii) the Shares are sold or transferred pursuant to Rule 144 of the Securities Act (“Rule

144”);

(b) any sale of the Shares made in reliance on Rule 144 may be made only in accordance with the terms of Rule

144 and, if Rule 144 is not applicable, any resale of the Shares under circumstances in which the seller (or the person through whom the sale is made) may be deemed to be an underwriter (as that term is defined in the Securities Act) may require

compliance with some other exemption under the Securities Act or the rules and regulations of the SEC thereunder;

acknowledges and agrees that the combination of BMS’s acquisition of the Shares pursuant to this Agreement and its rights pursuant to the License Agreement, taken alone and assuming no further acquisitions of Common Stock by BMS or any of its

subsidiaries or other changes to the relationship of the Parties, does not result in BMS being an affiliate of Immunome for purposes of Rule 144; and

(d) Subject to receipt from BMS by Immunome and Immunome’s transfer agent (the “Transfer Agent”) of

customary representations and other documentation reasonably acceptable to Immunome and the Transfer Agent in connection therewith, Immunome shall remove any legend from the book entry position evidencing the Shares issued hereunder and

Immunome will, if required by the Transfer Agent, use its commercially reasonable efforts to cause an opinion of Immunome’s counsel be provided, in a form reasonably acceptable to the Transfer Agent to the effect that the removal of such

restrictive legends in such circumstances may be effected under the Securities Act, (1) following the time the Resale Registration Statement is declared effective, or (2) if such Shares have been sold pursuant to Rule 144 or any other

applicable exemption from the registration requirements of the Securities Act. If restrictive legends are no longer required for such Shares pursuant to the foregoing, Immunome shall, in accordance with the provisions of this

Section 4.1(d) and within two business days of any request therefor from BMS accompanied by such customary and reasonably acceptable representations and other documentation referred to above establishing that restrictive

legends are no longer required, deliver to the Transfer Agent irrevocable instructions to make a new, unlegended entry for such book entry Shares. Notwithstanding the foregoing, within five business days following the

one-year anniversary of the Closing, Immunome shall remove, and shall direct the Transfer Agent to remove, any legend from the book entry position evidencing the Shares. BMS agrees with Immunome that BMS will

only sell Shares pursuant to either the registration requirements of the Securities Act, including any applicable prospectus delivery requirements, or an exemption therefrom, and that if Shares are sold pursuant to the Resale Registration Statement,

they will be sold in compliance with the plan of distribution set forth therein, and acknowledges that the removal of the restrictive legend from certificates representing Shares as set forth in

this Section 4.1(d) is predicated upon Immunome’s reliance upon this understanding.

4.2 Legends. BMS understands the Shares will bear the restrictive legend in

substantially the following form (and a stop-transfer order may be placed against transfer of the Shares):

THE SHARES HAVE NOT BEEN

REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO THE

SECURITIES UNDER SUCH ACT OR APPLICABLE STATE SECURITIES LAWS, PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OR UNLESS A CERTIFICATE AND/OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED HAS BEEN PROVIDED TO

THE COMPANY.

Section 5. REGISTRATION RIGHTS

5.1 Definitions. For the purpose of this Agreement:

(a) the term “Resale Registration Statement” shall mean any registration statement required to be filed by

Section 5.2, and shall include any preliminary prospectus, final prospectus, exhibit or amendment included in or relating to such registration statements; and

(b) the term “Registrable Shares” means the Shares and any Common Stock issued or issuable with respect to the

Shares as a result of any stock split or subdivision, stock dividend, recapitalization, exchange or similar event; provided, however, that a security shall cease to be a Registrable Share upon the earliest to occur of the following:

(i) a Resale Registration Statement registering such security under the Securities Act has been declared or becomes effective and such security has been sold or otherwise transferred by the holder thereof pursuant to and in a manner

contemplated by such effective Resale Registration Statement, (ii) such security is sold pursuant to Rule 144 under circumstances in which any legend borne by such security relating to restrictions on transferability thereof, under the

Securities Act or otherwise, is removed by Immunome, (iii) the first date such security is eligible to be sold pursuant to Rule 144 without any limitation as to volume of sales, holding period and without the holder complying with any method of

sale requirements or notice requirements under Rule 144, or (iv) such security shall cease to be outstanding following its issuance. Notwithstanding the foregoing, no Shares shall be Registrable Shares following the three-year anniversary of

the date the Mandatory Registration Statement is declared effective.

5.2 Registration Procedures. Immunome shall:

(a) use its commercially reasonable efforts to file a Resale Registration Statement (the “Mandatory Registration

Statement”) with the SEC within 45 days following the date of this Agreement (the “Filing Date”) to register all of the Registrable Shares on Form S-3 under the

Securities Act (providing for shelf registration of such Registrable Shares under SEC Rule 415) (or if Immunome is not then eligible to use Form S-3, Form S-1);

provided, that Immunome’s obligation to file a Resale Registration Statement (including the Mandatory Registration Statement) is contingent upon BMS furnishing in writing to Immunome such information regarding BMS, the securities of

Immunome held by BMS and the intended method of disposition of such Shares, which shall be limited to non-underwritten public offerings, as shall be reasonably requested by Immunome to effect the registration

of such Shares in compliance with applicable securities laws and which information shall be requested by Immunome from BMS at least five business days prior to the anticipated filing date of the Resale Registration Statement;

(b) use its commercially reasonable efforts to promptly cause such Mandatory

Registration Statement to be declared effective as soon as practicable after the filing thereof, but no later than the earlier of (i) 60 calendar days after the filing thereof in the event the SEC reviews and has written comments to the Resale

Registration Statement and (ii) the fifth business day after the date Immunome is notified (orally or in writing, whichever is earlier) by the SEC that the Resale Registration Statement will not be “reviewed” or will not be subject

to further review (the earlier of (i) and (ii), the “Effectiveness Deadline”); provided, that if such deadline falls on a Saturday, Sunday or other day that the SEC is closed for business, the Effectiveness

Deadline shall be extended to the next business day;

Registration Statement or any related prospectus or any amendment or supplement thereto, furnish via email to BMS copies of all such documents proposed to be filed (other than any document that is incorporated or deemed to be incorporated by

reference therein) for review by BMS. Immunome shall reflect in each such document when so filed with the SEC such comments regarding BMS and the plan of distribution as BMS may reasonably and promptly propose no later than two business days after

BMS has been so furnished with copies of such documents as aforesaid;

(d) promptly prepare and file with the SEC such amendments

and supplements to such Resale Registration Statements and the prospectuses used in connection therewith as shall be necessary to keep such Resale Registration Statements continuously effective and free from any material misstatement or omission to

state a material fact therein for so long as such Shares remain Registrable Shares, subject to Immunome’s right to suspend pursuant to Section 5.5;

(e) furnish to BMS such number of copies of prospectuses in conformity with the requirements of the Securities Act as BMS may reasonably

request, in order to facilitate the public sale or other disposition of all or any of the Registrable Shares by BMS;

(f) upon

notification by the SEC that the Resale Registration Statement has been declared effective by the SEC, Immunome shall, if required, file the final prospectus under Rule 424 of the Securities Act (“Rule 424”) within the

applicable time period prescribed by Rule 424;

(g) for so long as the Shares remain Registrable Shares, advise BMS:

(i) within one business day of the effectiveness of the Resale Registration Statement or any post-effective amendments thereto;

(ii) within five business days of any request by the SEC for amendments to the Resale Registration Statement or amendments to the

prospectus or for additional information relating thereto;

(iii) within one business day of the issuance by the SEC of any stop

order suspending the effectiveness of the Resale Registration Statement or the initiation of any proceedings for such purpose;

(iv) within one business day of the suspension of the qualification of the Registrable Shares for sale in any jurisdiction, or the

initiation of any proceeding for any of the preceding purposes; and

(v) within one business day of the existence of any fact and

the happening of any event that makes any statement of a material fact made in the Resale Registration Statement, the prospectus and amendment or supplement thereto, or any document incorporated by reference therein, untrue, or that requires the

making of any additions to or changes in the Resale Registration Statement or the prospectus in order to make the statements therein not misleading;

(h) cause all Registrable Shares to be listed on each securities exchange, if any, on

which equity securities by Immunome are then listed; and

(i) bear all expenses in connection with the procedures in paragraphs

(a) through (h) of this Section 5.2 and the registration of the Registrable Shares on such Resale Registration Statement.

5.3 Rule 415; Cutback. If the SEC prevents Immunome from including any or all of the Registrable Shares in a Resale Registration

Statement due to limitations on the use of Rule 415 under the Securities Act or requires BMS to be named as an “underwriter,” Immunome shall use its commercially reasonable efforts to persuade the SEC that the offering contemplated by

the Resale Registration Statement is a valid secondary offering and not an offering “by or on behalf of the issuer” as defined in Rule 415 and that BMS is not an “underwriter.” In the event that, despite Immunome’s

commercially reasonable efforts and compliance with the terms of this Section 5.3, the SEC refuses to alter its position, Immunome shall (i) remove from the Resale Registration Statement such portion of the Registrable

Shares (the “Cut Back Shares”) and/or (ii) agree to such restrictions and limitations on the registration and resale of the Registrable Shares as the SEC may require to assure Immunome’s compliance with the

requirements of Rule 415 (collectively, the “SEC Restrictions”); provided, however, that Immunome shall not agree to name BMS as an “underwriter” in such Resale Registration Statement without the

prior written consent of BMS. BMS acknowledges that it shall not have suffered any Losses (as defined below) as to any Cut Back Shares until the date that is five business days following the date that Immunome is eligible to bring effective the

registration of such Cut Back Shares in accordance with any SEC Restrictions (such date, the “Restriction Termination Date” of such Cut Back Shares). From and after the Restriction Termination Date applicable to any Cut

Back Shares, all of the provisions of this Section 5 shall again be applicable to such Cut Back Shares; provided, however, that the Filing Date for the Resale Registration Statement including such Cut Back Shares shall be

10 business days after such Restriction Termination Date, and Immunome shall use commercially reasonable efforts to cause such Resale Registration Statement to become effective as promptly as practicable.

5.4 Indemnification.

(a) Immunome agrees to indemnify and hold harmless BMS and its Affiliates, officers, directors, agents and representatives (each, a

“BMS Party” and collectively the “BMS Parties”), to the fullest extent permitted by applicable Law, from and against any losses, claims, damages or liabilities (collectively,

“Losses”) to which they may become subject (under the Securities Act or otherwise) insofar as such Losses (or actions or proceedings in respect thereof) arise out of, or are based upon, any material breach of this Agreement

by Immunome or any untrue statement or alleged untrue statement of a material fact contained in any Resale Registration Statement or any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make

the statements therein, in light of the circumstances under which they were made, not misleading or arise out of any failure by Immunome to fulfill any undertaking included in any Resale Registration Statement and Immunome will, as incurred,

reimburse the BMS Parties for any legal or other expenses reasonably incurred in investigating, defending or preparing to defend any such action, proceeding or claim; provided, however, that Immunome shall not be liable in any such

case to the extent that such Loss arises out of, or is based upon: (i) an untrue statement or omission or alleged untrue statement or omission made in such Resale Registration Statement based on written information furnished to Immunome by or

on behalf of BMS specifically for use in preparation of the Resale Registration Statement; or (ii) any breach of this Section 5 by BMS; provided further, however, that Immunome shall not be liable to any

BMS Party (or any officer, director or controlling person of BMS) to the extent that any such Loss is caused by an untrue statement or omission or alleged untrue statement or omission made in any preliminary prospectus if either (i) (A) BMS

failed to send or deliver a copy of the final prospectus with or prior to, or such BMS failed to confirm that a final prospectus was deemed to be delivered prior to (in accordance with Rule 172 of the Securities Act), the delivery of written

confirmation

of the sale by BMS to the person asserting the claim from which such Loss resulted and (B) the final prospectus corrected such untrue statement or omission, (ii) (X) such untrue

statement or omission is corrected in an amendment or supplement to the prospectus and (Y) having previously been furnished by or on behalf of Immunome with copies of the prospectus as so amended or supplemented or notified by Immunome that

such amended or supplemented prospectus has been filed with the SEC, in accordance with Rule 172 of the Securities Act, BMS thereafter fails to deliver such prospectus as so amended or supplemented, with or prior to or BMS fails to confirm that the

prospectus as so amended or supplemented was deemed to be delivered prior to (in accordance with Rule 172 of the Securities Act), the delivery of written confirmation of the sale by BMS to the person asserting the claim from which such Loss resulted

or (iii) BMS sold Registrable Shares in violation of its covenants contained in Section 3 of this Agreement.

(b) BMS

agrees to indemnify and hold harmless Immunome and its officers, directors, Affiliates, agents and representatives (each a “Company Party” and collectively the “Company Parties”), from and against

any Losses to which the Company Parties may become subject (under the Securities Act or otherwise), insofar as such Losses (or actions or proceedings in respect thereof) arise out of, or are based upon, any material breach of this Agreement by BMS

or untrue statement or alleged untrue statement of a material fact contained in any Resale Registration Statement (or any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements

therein, in light of the circumstances under which they were made, not misleading), but only to the extent such untrue statement or omission or alleged untrue statement or omission was made based on written information furnished by or on behalf of

BMS specifically for use in preparation of such Resale Registration Statement, and BMS will reimburse each Company Party for any legal or other expenses reasonably incurred in investigating, defending or preparing to defend any such action,

proceeding or claim; provided, however, that in no event shall any indemnity under this Section 5.4(b) be greater in amount than the dollar amount of the net proceeds received by BMS upon its sale of the Registrable Shares

included in the Resale Registration Statement giving rise to such indemnification obligation (such amount, the “Liability Cap”).

(c) Promptly after receipt by any indemnified person of a notice of a claim or the beginning of any action in respect of which indemnity

is to be sought against an indemnifying person pursuant to this Section 5.4, such indemnified Person shall notify the indemnifying Person in writing of such claim or of the commencement of such action, and, subject to the

provisions hereinafter stated, in case any such action shall be brought against an indemnified Person and such indemnifying Person shall have been notified thereof, such indemnifying Person shall be entitled to participate therein, and, to the

extent that it shall wish, to assume the defense thereof, with counsel reasonably satisfactory to such indemnified Person. After notice from the indemnifying Person to such indemnified Person of its election to assume the defense thereof, such

indemnifying Person shall not be liable to such indemnified Person for any legal expenses subsequently incurred by such indemnified Person in connection with the defense thereof; provided, however, that if there exists or shall exist a conflict of

interest that would make it inappropriate, based on the opinion of counsel, for the same counsel to represent both the indemnified Person and such indemnifying Person or any affiliate or associate thereof, the indemnified Person shall be entitled to

retain its own counsel at the expense of such indemnifying Person; provided, further, that no indemnifying Person shall be responsible for the fees and expense of more than one separate counsel for all indemnified parties. The indemnifying party

shall not settle an action without the consent of the indemnified party, which consent shall not be unreasonably withheld, conditioned or delayed; provided that no consent shall be required if such settlement contains an unconditional release of the

indemnified party from all liability arising out of such action or claim and does not include a statement as to or an admission of fault, culpability or failure to act by or on behalf of any indemnified party.

(d) If the indemnification provided for in this Section 5.4

is held by a court of competent jurisdiction to be unavailable to an indemnified party with respect to any losses, claims, damages or liabilities referred to herein, the indemnifying party, in lieu of indemnifying such indemnified party thereunder,

shall to the extent permitted by applicable Law contribute to the amount paid or payable by such indemnified party as a result of such loss, claim, damage or liability in such proportion as is appropriate to reflect the relative fault of the

indemnifying party on the one hand and of the indemnified party on the other, as well as any other relevant equitable considerations; provided, that in no event shall any contribution by BMS hereunder be greater than the Liability Cap.

5.5 Prospectus Suspension. BMS acknowledges that there may be times when Immunome must suspend the use of the prospectus forming

a part of the Resale Registration Statement until such time as an amendment to the Resale Registration Statement has been filed by Immunome and declared effective by the SEC, or until such time as Immunome has filed an appropriate report with the

SEC pursuant to the Exchange Act. BMS hereby covenants that it will not sell any Registrable Shares pursuant to said prospectus during the period commencing at the time at which Immunome gives BMS notice of the suspension of the use of said

prospectus and ending at the time Immunome gives BMS notice that BMS may thereafter effect sales pursuant to said prospectus; provided, (i) that such suspension periods shall in no event exceed (A) on more than three occasions, a period of

more than 30 consecutive business days or (B) more than an aggregate total of 60 business days, in each case in any 360-day period, and (ii) Immunome’s board of directors has reasonably

determined that, in order for such Resale Registration Statement not to contain a material misstatement or omission, an amendment thereto would be needed to include information that would at that time not otherwise be required in a current,

quarterly or annual report under the Exchange Act.

5.6 Reporting Requirements.

(a) With a view to making available the benefits of certain rules and regulations of the SEC that may at any time permit the sale of the

Shares to the public without registration or pursuant to a registration statement so long as BMS owns Shares, Immunome agrees to use commercially reasonable efforts to:

(i) make and keep public information available, as those terms are understood and defined in Rule 144; and

(ii) file with the SEC in a timely manner all reports and other documents required of Immunome under the Securities Act and the

Exchange Act.

Section 6. CLOSING CONDITIONS.

6.1 Conditions to Obligations of Immunome. Immunome’s obligation to complete the issuance of the Shares and deliver the

Shares to BMS is subject to the fulfillment or waiver of the following conditions at or prior to the Closing:

(a)

Representations and Warranties. The representations and warranties made by BMS in Section 3 will be true and correct in all material respects as of the date of the Closing, except to the extent such representations

and warranties are made as of another date, in which case such representations and warranties will be true and correct in all material respects as of such other date, except in each case where the failure of such representations and warranties to be

so true and correct (without giving effect to any limitation as to “materiality” set forth therein) would not reasonably be expected to have a material adverse effect on BMS’ ability to perform its obligations hereunder or

consummate the transactions contemplated hereby.

(b) Covenants. All covenants and agreements contained in this Agreement to be

performed or complied with by BMS on or prior to the date of the Closing shall have been performed or complied with in all material respects.

(c) Absence of Litigation. No proceeding challenging this Agreement or the transactions contemplated hereby, or seeking to

prohibit, alter, prevent or materially delay the Closing, will have been instituted or be pending before any Governmental Authority.

(d) License Agreement Amendment. BMS shall have duly executed and delivered the Amendment to Immunome, and subject to execution

by Immunome, such agreement shall be in full force and effect.

(e) Nasdaq Qualification. Nasdaq shall have raised no

objection to the consummation of the transactions contemplated by this Agreement in the absence of stockholder approval of such transactions.

(f) No Governmental Prohibition. The issuance of the Shares by Immunome, and the acquisition of the Shares by BMS will not be

prohibited by any applicable Law or governmental order or regulation.

(g) Officer’s Certificate. BMS shall have

delivered to Immunome a certificate in form and substance reasonably satisfactory to Immunome and duly executed on behalf of BMS by an authorized officer of BMS, certifying that the conditions to the Closing set forth in this

Section 6.1 (other than with respect to clause (d) of this Section 6.1) have been fulfilled.

6.2 Conditions to BMS’ Obligations at the Closing. BMS’ obligation to complete the acquisition of the Shares is

subject to the fulfillment or waiver of the following conditions at or prior to the Closing:

(a) Representations and

Warranties. The representations and warranties made by Immunome in Section 2 will be true and correct in all material respects as of the date of the Closing, except to the extent such representations and warranties are

made as of another date, in which case such representations and warranties will be true and correct in all material respects as of such other date, except in each case where the failure of such representations and warranties to be so true and

correct (without giving effect to any limitation as to “materiality” set forth therein) would not reasonably be expected to have a Material Adverse Effect on Immunome’s ability to perform its obligations hereunder or consummate the

transactions contemplated hereby.

(b) Covenants. All covenants and agreements contained in this Agreement to be performed or

complied with by Immunome on or prior to the date of the Closing shall have been performed or complied with in all material respects.

(c) Transfer Agent Instructions. Immunome will have delivered to the Transfer Agent irrevocable written instructions to issue the

Shares to BMS in a form and substance acceptable to the Transfer Agent.

(d) Nasdaq Qualification. On or prior to the date

hereof, Immunome shall have taken all actions which are reasonably necessary, including, if applicable, providing appropriate notice to Nasdaq of the transactions contemplated by this Agreement, for the Shares to be listed on Nasdaq and shall have

complied with all listing, reporting, filing and other obligations under the rules of Nasdaq and of the SEC with respect to the matters contemplated by this Agreement, and Nasdaq shall have raised no objection to

the consummation of the transactions contemplated by this Agreement in the absence of stockholder approval of such transactions. The Common Stock shall not have been suspended, as of the date of

the Closing, by the SEC or Nasdaq from trading on Nasdaq nor shall any such suspension by the SEC or Nasdaq have been threatened, as of the date of the Closing, in writing by the SEC or Nasdaq.

(e) Absence of Litigation. No proceeding challenging this Agreement or the transactions contemplated hereby, or seeking to

prohibit, alter, prevent or materially delay the Closing, will have been instituted or be pending before any Governmental Authority.

(f) License Agreement Amendment. Immunome shall have duly executed and delivered the Amendment to BMS, and subject to execution

by BMS, such agreement shall be in full force and effect.

(g) No Governmental Prohibition. The issuance of the Shares by

Immunome, and the acquisition of the Shares by BMS will not be prohibited by any applicable Law or governmental order or regulation.

(h) Officers’ Certificate. Immunome shall have delivered to BMS a certificate in form and substance reasonably satisfactory

to BMS and duly executed on behalf of Immunome by an authorized officer of Immunome, certifying that the conditions to the Closing set forth in this Section 6.2 have been fulfilled.

Section 7. GOVERNING LAW; MISCELLANEOUS.

7.1 Governing Law. This Agreement will be governed by and interpreted in accordance with the substantive laws of the State of

Delaware, U.S. without regard to its or any other jurisdiction’s laws, rules or principles that would result in the application of the laws of any jurisdiction other than the State of Delaware.

7.2 Survival. The provisions of Section 5 and the representations and warranties of Immunome and BMS contained in this

Agreement shall survive the Closing and delivery of the Shares.

7.3 Counterparts; Electronic Signatures. This Agreement may

be executed in counterparts, and each such counterpart hereof will be deemed to be an original instrument, but all such counterparts together will constitute but one agreement. Delivery of an executed counterpart of a signature page of this

Agreement by PDF, facsimile or other electronic transmission will be effective as delivery of a manually executed original counterpart of this Agreement.

7.4 Headings. The headings of this Agreement are for convenience of reference only, are not part of this Agreement and do not

affect its interpretation.

7.5 Severability. Whenever possible, each provision of this Agreement will be interpreted in such

manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision will be ineffective only to the extent of such prohibition or invalidity,

without invalidating the remainder of this Agreement. In the event of such invalidity, the Parties will seek to agree on an alternative enforceable provision that preserves the original purpose of this Agreement.

7.6 Entire Agreement; Amendments. This Agreement and the appendix attached

hereto, and the License Agreement, constitute and contain the complete, final and exclusive understanding and agreement of the Parties, and cancel and supersede any and all prior or contemporaneous negotiations, correspondence, understandings and

agreements, whether oral or written, between the Parties respecting the subject matter of this Agreement, and neither Party will be liable or bound to any other Party in any manner by any representations, warranties, covenants, or agreements except

as specifically set forth herein or therein. Nothing in this Agreement, express or implied, is intended to confer upon any Party, other than the Parties and their respective successors and assigns, any rights, remedies, obligations, or liabilities

under or by reason of this Agreement, except as expressly provided herein. No amendment, modification or supplement of any provision of this Agreement will be valid or effective unless made in writing and signed by a duly authorized officer of each

Party.

7.7 Notices. All notices, consents, waivers and other communications required or permitted to be given hereunder

shall be deemed given (a) when receipt is acknowledged (including read receipt) if sent by email, (b) the second business day (at the place of delivery) after deposit with an internationally recognized overnight delivery service, or

(c) the fifth business day after mailing if mailed by registered or certified mail, postage prepaid and return receipt requested, in each case to the addresses set forth below or to such other addresses of which notice shall have been given in

accordance with this Section 7.7.

If to Immunome:

Immunome, Inc.

18702 N. Creek

Parkway

Suite 100

Bothell,

WA 98011

Attention: Chief Legal Officer

E-mail: [***]

If to BMS:

Bristol-Myers

Squibb Company

Route 206 & Province Line Road

Princeton, NJ 08543

Attention:

Senior Vice President, Business Development

Email: [***]; with a copy to [***]

7.8 Successors and Assigns. This Agreement is binding upon and inures to the benefit of the parties and their successors and

assigns. Immunome will not assign this Agreement or any rights or obligations hereunder without the prior written consent of BMS, and BMS will not assign this Agreement or any rights or obligations hereunder without the prior written consent of

Immunome; provided, however, that BMS may assign this Agreement together with all of the Shares it then owns (subject to Section 4) to any wholly-owned subsidiary and any such assignee may assign the Agreement

together with all of the Shares it then owns (subject to Section 4) to BMS or any other subsidiary wholly-owned by BMS, in any such case, without such consent provided that the assignee agrees to assume BMS’

obligations under Section 4 of this Agreement.

7.9 Third Party Beneficiaries. This Agreement is

intended for the benefit of the Parties hereto, their respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person.

7.10 Further Assurances. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other

acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.

7.11 No Strict Construction. The language used in this Agreement is

deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against a party.

7.12 Equitable Relief. Immunome recognizes that, if it fails to perform or discharge any of its obligations under this Agreement,

any remedy at law may prove to be inadequate relief to BMS. Immunome therefore agrees that BMS is entitled to seek temporary and permanent injunctive relief or specific performance in any such case from any court having jurisdiction over the

Parties. BMS also recognizes that, if it fails to perform or discharge any of its obligations under this Agreement, any remedy at law may prove to be inadequate relief to Immunome. BMS therefore agrees that Immunome is entitled to seek temporary and

permanent injunctive relief or specific performance in any such case from any court having jurisdiction over the Parties.

7.13

Expenses. Immunome and BMS are each liable for, and will pay, their own expenses incurred in connection with the negotiation, preparation, execution and delivery of this Agreement, including, without limitation, attorneys’ and

consultants’ fees and expenses; provided, however, that Immunome shall pay all Transfer Agent fees (including, without limitation, any fees required for same-day processing of any instruction letter

delivered by Immunome), stamp taxes and other taxes (other than income taxes) and duties levied in connection with the delivery of the Shares (and any Common Stock issued or issuable with respect to the Shares as a result of any stock split or

subdivision, stock dividend, recapitalization, exchange or similar event) to BMS.

7.14 No Publicity. Immunome hereby

agrees that no announcement regarding BMS or its Affiliates, or use of any of their respective names or other identifying information, or the material terms of the transactions contemplated hereby, in a press release, conference, advertisement,

announcement, professional or trade publication, social media post, mass marketing materials or other materials otherwise available to the general public may be made without BMS’s prior written consent, provided, however, that

Immunome and BMS agree that the foregoing does not prohibit Immunome from disclosures based on the advice of Immunome’s counsel that are required in order to comply with applicable governmental orders, Laws, rules or regulations, and in the

case of any such disclosure, Immunome will provide BMS with prompt written notice of the applicable portion of such disclosure; provided, further, however, that, except where legally prohibited, such notice shall be given to BMS prior to such

disclosure and, reasonably in advance of such disclosure, Immunome shall give BMS an opportunity to review and comment on the applicable portion of such disclosure.

7.15 Physical Certificates. Immunome will use commercially reasonable efforts to provide BMS with the right to receive physical

certificates representing the shares of equity securities of Immunome held by BMS or any securities into which such shares are converted or for which they are exchanged (as adjusted for any stock splits, dividends, combinations or other

reclassification effected after the date hereof), subject to BMS’s compliance with any requirements from the Transfer Agent with respect to delivery of such physical certificate.

7.16 Definitions. In addition to the terms defined elsewhere in this Agreement, the following terms have the meanings set forth

in this Section 7.16:

“Affiliate” of an entity means any corporation, firm,

partnership or other entity that directly or indirectly through one or more intermediaries controls, is controlled by or is under common control with it, for so long as such control exists. An entity will be deemed to control another entity if it

(i) owns, directly or indirectly, at least 50% of the outstanding voting securities or capital stock (or such lesser percentage that is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) of such other entity,

or has other comparable ownership interest with respect to any entity other than a corporation; or (ii) has the power, whether pursuant to contract, ownership of securities or otherwise, to direct the management and policies of the entity.

“GAAP” means generally accepted accounting principles and

practices in effect from time to time within the United States applied consistently throughout the period involved.

“Governmental Authority” means any federal, state, provincial, local, municipal, foreign or other governmental or

quasi-governmental authority, including without limitation any arbitrator and applicable securities exchanges, or any department, minister, agency, commission, commissioner, board, subdivision, bureau, agency, instrumentality, court or other

tribunal of any of the foregoing.

“Intellectual Property Rights” means all past, present, and future rights of

the following types, which may exist or be created under the laws of any jurisdiction in the world: (a) rights associated with works of authorship, including exclusive exploitation rights, copyrights, moral rights, software, databases, and mask

works; (b) trademarks, service marks, trade dress, logos, trade names and other source identifiers, domain names and URLs and similar rights and any goodwill associated therewith; (c) rights associated with trade secrets, know how,

inventions, invention disclosures, methods, processes, protocols, specifications, techniques and other forms of technology; (d) patents and industrial property rights; and (e) other similar proprietary rights in intellectual property of

every kind and nature; (f) rights of privacy and publicity; and (g) all registrations, renewals, extensions, statutory invention registrations, provisionals, continuations,

continuations-in-part, divisions, or reissues of, and applications for, any of the rights referred to in clauses (a) through (f) above (whether or not in tangible

form and including all tangible embodiments of any of the foregoing, such as samples, studies and summaries), along with all rights to prosecute and perfect the same through administrative prosecution, registration, recordation or other

administrative proceeding, and all causes of action and rights to sue or seek other remedies arising from or relating to the foregoing.

“Law” means any federal, state, national, foreign, material local or municipal or other law, statute, constitution,

principle of common law, resolution, ordinance, code, edict, decree, rule, regulation, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Authority

(including under the authority of Nasdaq or the Financial Industry Regulatory Authority).

“Tax” means any

federal, state, local, foreign or other tax, including any income, capital gain, gross receipts, capital stock, profits, transfer, estimated, registration, stamp, premium, escheat, unclaimed property, customs duty, ad valorem, occupancy, occupation,

alternative, add-on, windfall profits, value added, severance, property, business, production, sales, use, license, excise, franchise, employment, payroll, social security, disability, unemployment,

workers’ compensation, national health insurance, withholding or other taxes, duties, fees, assessments or governmental charges, surtaxes or deficiencies thereof in the nature of a tax, however denominated, and including any fine, penalty,

addition to tax or interest imposed by a Governmental Authority with respect thereto.

“Tax Return” means any

return (including any information return), report, statement, declaration, estimate, schedule, notice, notification, form, election, certificate or other document or information, and any amendment or supplement to any of the foregoing, filed with or

submitted to, or required to be filed with or submitted to, any Governmental Authority in connection with the determination, assessment, collection or payment of any Tax or in connection with the administration, implementation or enforcement of or

compliance with any Law relating to any Tax.

[Remainder of page intentionally left blank.]

IN WITNESS WHEREOF,

BMS and Immunome have caused this Agreement to be duly executed as of the date first above written.

BRISTOL-MYERS SQUIBB COMPANY

By:

/s/ Sandra Ramos-Alves

Name:

Sandra Ramos-Alves

Its:

Senior Vice President and Treasurer

IMMUNOME, INC.

By:

/s/ Clay Siegall

Name:

Clay Siegall, Ph.D.

Its:

President and Chief Executive Officer

[Signature page to Stock Issuance Agreement]

EX-10.1

Filename: d114908dex101.htm · Sequence: 3

EX-10.1

Exhibit 10.1

CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT

MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

AMENDMENT NO. 4 TO LICENSE AGREEMENT

This AMENDMENT NO. 4 TO LICENSE AGREEMENT (“Amendment No. 4”) made and effective as

of October 2, 2026 (the “Amendment No. 4 Effective Date”), is by and between Immunome, Inc., a Delaware corporation with offices at 18702 N Creek Parkway South, Suite #100, Bothell,

WA 98011 (“Immunome”) and Bristol-Myers Squibb Company, a Delaware corporation with offices at Route 206 and Province Line Road, Princeton, New Jersey 08543 (“BMS”). Immunome and BMS are

together referred to in this Amendment No. 4 as the “Parties” and individually as a “Party.”

Background:

BMS and

Immunome (as assignee of Ayala Pharmaceuticals, Inc.) are parties to a License Agreement dated as of November 29, 2017 (as previously amended, the “License Agreement”). Capitalized terms used but not otherwise defined

in this Amendment No. 4 shall have the meanings assigned to them in the License Agreement.

The Parties now wish to amend the License

Agreement, pursuant to which BMS will assign to Immunome certain Patent Rights licensed to Immunome under the License Agreement, and the Parties will amend certain provisions of the License Agreement in connection therewith, in accordance with the

terms set forth below.

Terms:

NOW, THEREFORE, in consideration of the foregoing and other good and valuable consideration, the receipt and sufficiency of which are hereby

acknowledged, the Parties agree as follows:

1. Assignment of Certain Patents; Grant Back License.

(a) At and effective as of the Amendment No. 4 Effective Date, subject to receipt of the consideration specified in Section 2 and

Section 3 below, BMS shall, and shall cause its applicable Affiliates to, sell, transfer, convey, assign and deliver to Immunome, and Immunome shall purchase and accept from BMS (or an Affiliate of BMS), all of BMS’s (or such

Affiliate’s) right, title and interest in and to the Patent Rights set forth on Exhibit A (the “Transferred Patents”), free and clear of any encumbrance, lien or claim of ownership of any Third Party other than any

encumbrance disclosed on Schedule 1.

(b) On the Amendment No. 4 Effective Date, each of Immunome and BMS shall deliver to the other

the Bill of Sale in the form attached hereto as Exhibit B and the Patent Assignment attached hereto as Exhibit C.

(c)

Immunome shall grant and hereby grants to BMS a perpetual, irrevocable, worldwide, fully paid up, non-exclusive license under Immunome’s and its Affiliates’ interest in the Transferred Patents to

research, discover, make, have made, use, sell, offer to sell, export, import, develop and commercialize any molecules other than the Licensed Compounds and Licensed Products, which license shall be sublicensable through multiple tiers of

sublicenses to one or more of its Affiliates or Third Parties.

(d) Paragraph 6 of Amendment No. 2 to License Agreement by and between the Parties

dated as of August 7, 2024 is hereby deleted in its entirety and replace with the word “RESERVED”.

2. Cash

Payment. Section 8.2 of the License Agreement (Milestone Payments) is hereby deleted in its entirety and replaced with the following:

8.2 Cash Payment. On the Amendment No. 4 Effective Date, as partial consideration for BMS entering into this

Amendment No. 4, Immunome shall pay to BMS a nonrefundable, noncreditable payment of Twenty Million Dollars ($20,000,000) in cash by wire transfer into an account designated in writing by BMS.

3. Stock Issuance. Section 8.4 of the License Agreement (Royalty Payments) is hereby deleted in its entirety and replaced with the

following:

8.4 Stock Issuance. Concurrently with the execution of this Amendment No. 4, as partial

consideration for BMS entering into this Amendment No. 4, Immunome shall issue to BMS 4,425,487 shares of Immunome common stock, par value $0.0001 per share, pursuant to a stock issuance agreement executed by Immunome and BMS concurrently with

the execution of this Amendment No. 4.

4. License Grant Amendments.

(a) Section 1.5 of the License Agreement (definition of “BMS Patent Rights”) is hereby deleted in its entirety and replaced with

the word “RESERVED”. In connection with the consummation of the transactions contemplated by Section 1(a), the Parties acknowledge that, from and after the Amendment No. 4 Effective Date, there shall be no BMS Patent Rights

under the License Agreement, and any reference in the License Agreement to “BMS Patent Rights” shall have no further force or effect with respect to any period from and after the Amendment No. 4 Effective Date; [***]. Without

limiting the foregoing, the license grant under the BMS Patent Rights under Section 2.1 of the License Agreement (BMS Patent Rights and BMS Know-How) is hereby terminated as of the Amendment No. 4

Effective Date and all rights of Company under the BMS Patent Rights (other than the BMS Patent Rights that have become Transferred Patents hereunder) shall revert to BMS, and Company and its Affiliates shall have no rights to use, and shall not

use, such BMS Patent Rights.

(b) Section 2.2.1(e) of the License Agreement is hereby deleted in its entirety and replaced with the

following:

(e) the Sublicensee shall agree in writing to be bound by and comply with the terms and conditions of this

Agreement in the same manner as Company;

and replaced with the following:

2.5 Retained Rights. All rights not expressly granted by a Party hereunder

are reserved by such Party and may be used by such Party for any purpose. Without limiting the foregoing, BMS retains all rights to use and for its Affiliates to use the Licensed Compounds, the BMS Know-How

and the BMS Patent Rights for any internal research purposes in the Field to research, develop and commercialize any molecules other than the Licensed Compounds and Licensed Products, and for the manufacture of any compound that is not a Licensed

Compound, provided that such molecules and/or compounds are not Notch Inhibitors as their primary mechanism of action. BMS also expressly reserves and retains the right to make, have made and use any Licensed Compound for use as an intermediate or

starting material in the manufacture of any compound that is not a Licensed Compound. Nothing in this Agreement shall prevent BMS and its Affiliates from using for any purpose any BMS Know-How that is in the

public domain as of the Effective Date (or enters the public domain thereafter) and is not covered by a Valid Claim of a Transferred Patent.

5. Sales Reports, Sales Record Audit and Company Financial Report. Section 8.6 of the License Agreement (Sales Reports and Royalty

Payments), Section 8.7 of the License Agreement (Sales Record Audit) and Section 8.11 of the License Agreement (Company Financial Report) are each hereby deleted in their entirety and replaced, in all cases, with the word

“RESERVED”.

6. Development and Commercialization Diligence and Reports. The following sections of the License

Agreement are hereby deleted in their entirety and replaced, in all cases, with the word “RESERVED”: Section 5.1 (Development); Section 5.2 (Development Reports); Section 5.3 (Records); Section 6.1 (Company Obligations);

Section 6.2 (Continued Availability); and Section 6.3 (Reports).

7. Section 8.9 of the License Agreement (Taxes) is hereby

amended and restated in its entirety as follows:

8.9 Taxes. Each Party will pay any and all taxes

levied on account of all payments it receives under this Agreement. Company shall be responsible for paying all indirect taxes (such as value added tax, sales tax, consumption tax and other similar taxes, including any transfer, documentary, use,

stamp, goods and services, excise, registration or other similar tax), and all conveyance fees, recording charges and other fees and charges incurred in connection with this Agreement, the Bill of Sale, the Patent Assignment, and any other

transaction documents.

8. Patent Prosecution and Enforcement. The following sections of the License Agreement are hereby deleted

in their entirety and replaced, in all cases, with the word “RESERVED”: Section 10.2 (Filing, Prosecution and Maintenance of BMS Patent Rights); Section 10.3 (Patent Abandonment); Section 10.4 (Enforcement of BMS Patent

Rights against Infringers); Section 10.6 (Patent Extensions); Section 10.7 (Data Exclusivity and Orange Book Listings); Section 10.8 (Notification of Patent Certification); Section 10.9 (No Conflict Actions); and

Section 10.10 (Assignment of BMS Patent Rights).

9. Term.

(a) Section 13.1 of the License Agreement (Term) is hereby amended and restated in its entirety as follows:

13.1 Term. This Agreement shall commence as of the Effective Date and, unless sooner terminated in accordance

with the terms hereof or by mutual written consent, shall expire on a country-by-country basis and Licensed Product-by-Licensed Product basis, upon the expiration of the last-to-expire Valid Claim of the Transferred Patents claiming

such Licensed Product in such country.

(b) Section 13.2 of the License Agreement (Termination by BMS) is hereby deleted in its entirety

and replaced with the word “RESERVED.”

its entirety and replaced with the word “RESERVED.”

(d) The header of Section 13.5 of the License Agreement “Effect

of Termination by Company for Breach by BMS” is hereby replaced with “Effect of Termination by Company”; the reference to Section 13.3.2 in Section 13.5 of the License Agreement is hereby replaced with a reference to

Section 13.3; and Section 13.5.4 is hereby deleted in its entirety and replaced with the word “RESERVED”.

(e)

Section 13.6.4 of the License Agreement is hereby amended and restated in its entirety as follows:

13.6.4 The

license with respect to the BMS Know-How granted under Section 2.1 shall convert to a non-exclusive, perpetual, irrevocable, fully

paid-up license.

(e) Section 13.8 of the License Agreement (Survival) is hereby amended and

restated in its entirety as follows:

13.8 Survival. The following provisions shall survive termination or

expiration of this Agreement, as well as any other provisions which by their nature are intended to survive termination: Article 1 (as applicable), Sections 8.8 through 8.10 (for [***] after the end of the Calendar Year in which this Agreement was

terminated), Section 9.4, Section 9.5, Section 10.1, Article 11, Article 12, whichever one of Sections 13.5 or 13.6 applies, Section 13.7, this Section 13.8, Section 13.9, Section 13.10, Article 14 and Article 15.

10. Assignment. Section 15.4.2 is hereby amended and restated in its entirety to read as follows:

15.4.2 Company may assign or transfer this Agreement or all of its rights and obligations hereunder without BMS’s consent

to a successor in interest by reason of merger, consolidation or sale of substantially all of the assets of Company to which this Agreement relates (and so long as such assignment or transfer includes, without limitation, all Approvals, all

manufacturing rights with respect to such assets, and all rights and obligations under this Agreement); provided, however, that such successor in interest shall have agreed prior to such assignment or transfer to be bound by the terms

of this Agreement in a writing provided to BMS.

11. Mutual Representations and Warranties. Each Party represents and warrants to the

other Party that, as of the date of this Amendment No. 4: (i) it is duly organized, validly existing and in good standing under the Laws of the jurisdiction of its incorporation and has all requisite corporate power and authority to enter into

this Amendment No. 4 and to perform its obligations under this Amendment No. 4, (ii) execution of this Amendment No. 4 and the performance by such Party of its obligations hereunder have been duly authorized, (iii) this Amendment

No. 4 has been duly executed and delivered on behalf of such Party, and is legally binding and enforceable on each Party in accordance with its terms, (iv) the performance of this Amendment No. 4 by it does not create a breach or

default under any other agreement to which it is a Party, and (v) the execution, delivery and performance of this Amendment No. 4 by such Party does not conflict with any agreement, instrument or understanding, oral or written, to which it

is a party or by which it is bound.

12. Full Force and Effect. Except as expressly amended hereby, the License Agreement shall

remain unchanged and in full force and effect in accordance with its original terms; provided that, to the extent that any of the terms and conditions of this Amendment No. 4 are inconsistent with the terms and conditions of the License

Agreement, the terms of this Amendment No. 4 will govern.

13. Governing Law. This Amendment No. 4 shall be governed by,

enforced, and shall be construed in accordance with the laws of the State of Delaware without regard to its conflicts of law provisions.

14. Miscellaneous. This Amendment No. 4 may be executed by the Parties on separate counterparts, both of which shall be an

original and both of which together shall constitute one and the same agreement. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g.,

www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. At either Party’s request, the other Party shall execute and

deliver such additional documents and instruments, including confirmatory assignments, documents in local form and documents requiring notarization, legalization, apostille, certification or translation, as may be required or reasonably requested to

evidence, perfect or record the transfer of the Transferred Patents and the other transactions contemplated by this Agreement.

[Signature

Page Follows]

IN WITNESS WHEREOF, the Parties have executed this Amendment No. 4 as of the Amendment

No. 4 Effective Date.

BRISTOL-MYERS SQUIBB COMPANY

By:

/s/ Siobhan Pomeroy

Name: Siobhan Pomeroy

Title: Senior Vice President, M&A and BD&L Transactions

IMMUNOME, INC.

By:

/s/ Clay Siegall

Name: Clay Siegall, Ph.D.

Title: President and Chief Executive Officer

[Signature Page to Amendment No. 4 to License Agreement]

Exhibit A

Transferred Patents

[***]

Exhibit B

BILL OF SALE AND

ASSIGNMENT AND ASSUMPTION AGREEMENT

[***]

Exhibit C

PATENT ASSIGNMENT AGREEMENT

[***]

Schedule 1

Permitted Encumbrances

[***]

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.3

Document and Entity Information

Oct. 02, 2026

Cover [Abstract]

Entity Registrant Name

Immunome Inc.

Security Exchange Name

NASDAQ

Amendment Flag

false

Entity Central Index Key

0001472012

Document Type

8-K

Document Period End Date

Oct. 02, 2026

Entity Incorporation State Country Code

Entity File Number

001-39580

Entity Tax Identification Number

77-0694340

Entity Address, Address Line One

18702 N. Creek Parkway

Entity Address, Address Line Two

Suite 100

Entity Address, City or Town

Bothell

Entity Address, State or Province

Entity Address, Postal Zip Code

98011

City Area Code

425

Local Phone Number

939-7410

Written Communications

false

Soliciting Material

false

Pre Commencement Tender Offer

false

Pre Commencement Issuer Tender Offer

false

Security 12b Title

Common Stock, $0.0001 par value per share

Trading Symbol

IMNM

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration